Literature DB >> 17375904

Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1.

Luc Demange1, Damien Boeglin, Aline Moulin, Delphine Mousseaux, Joanne Ryan, Gilbert Bergé, Didier Gagne, Annie Heitz, Daniel Perrissoud, Vittorio Locatelli, Antonio Torsello, Jean-Claude Galleyrand, Jean-Alain Fehrentz, Jean Martinez.   

Abstract

A new series of growth hormone secretagogue (GHS) analogues based on the 1,2,4-triazole structure were synthesized and evaluated for their in vitro binding and their ability to stimulate intracellular calcium release to the cloned hGHS-1a ghrelin receptor expressed in LLC PK-1 cells. We have synthesized potent ligands of this receptor, some of them behaving as agonists, partial agonists, or antagonists. Some compounds among the most potent, i.e., agonist 29c (JMV2873), partial agonists including 21b (JMV2810), antagonists 19b (JMV2866) and 19c (JMV2844), were evaluated for their in vivo activity on food intake, after sc injection in rodents. Some compounds were found to stimulate food intake like hexarelin; some others were identified as potent hexarelin antagonists in this assay. Among the tested compounds, 21b was identified as an in vitro ghrelin receptor partial agonist, as well as a potent in vivo antagonist of hexarelin-stimulated food intake in rodents. Compound 21b was without effect on GH release from rat. However, in this series of compounds, it was not possible to find a clear correlation between in vitro and in vivo results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375904     DOI: 10.1021/jm070024h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

Review 1.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

Review 2.  Therapy for obesity based on gastrointestinal hormones.

Authors:  Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.

Authors:  Elena Bresciani; Laura Rizzi; Laura Molteni; Monica Ravelli; Antonella Liantonio; Khoubaib Ben Haj Salah; Jean-Alain Fehrentz; Jean Martinez; Robert J Omeljaniuk; Giuseppe Biagini; Vittorio Locatelli; Antonio Torsello
Journal:  Endocrine       Date:  2016-11-28       Impact factor: 3.633

4.  Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.

Authors:  Suvi T M Orr; Ramsay Beveridge; Samit K Bhattacharya; Kimberly O Cameron; Steven Coffey; Dilinie Fernando; David Hepworth; Margaret V Jackson; Vishal Khot; Rachel Kosa; Kimberly Lapham; Paula M Loria; Kim F McClure; Jigna Patel; Colin Rose; James Saenz; Ingrid A Stock; Gregory Storer; Maria von Volkenburg; Derek Vrieze; Guoqiang Wang; Jun Xiao; Yingxin Zhang
Journal:  ACS Med Chem Lett       Date:  2014-12-14       Impact factor: 4.345

5.  Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice.

Authors:  Alexander V Mayorov; Neri Amara; Jason Y Chang; Jason A Moss; Mark S Hixon; Diana I Ruiz; Michael M Meijler; Eric P Zorrilla; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

6.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

Review 7.  Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

8.  Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Authors:  Rasha Mosa; Lili Huang; Yeda Wu; Chungyan Fung; Oshini Mallawakankanamalage; Derek LeRoith; Chen Chen
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

9.  Recent advances in potential clinical application of ghrelin in obesity.

Authors:  Christine Delporte
Journal:  J Obes       Date:  2012-02-20

10.  Actions of Agonists and Antagonists of the ghrelin/GHS-R Pathway on GH Secretion, Appetite, and cFos Activity.

Authors:  Rim Hassouna; Alexandra Labarthe; Philippe Zizzari; Catherine Videau; Michael Culler; Jacques Epelbaum; Virginie Tolle
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.